MALVERN, PA — Endo, Inc. (OTCQX: NDOI) has unveiled promising data from its Phase 2 clinical study of collagenase clostridium histolyticum (CCH) in treating plantar fibromatosis, presented at the American Orthopaedic Foot & Ankle Society’s annual meeting. This study is pivotal for Endo’s future musculoskeletal pipeline, focusing on alleviating pain and improving conditions associated with plantar fibromatosis.
The study, entitled “A Phase 2, Double-blind, Randomized, Placebo-Controlled Study,” indicates that CCH shows a positive trend in reducing pain and improving nodular hardness and consistency compared to placebo. The safety profile of CCH was consistent with previous studies, showing most adverse events as mild to moderate with no serious treatment-related incidents.
“Our clinical programs for plantar fibromatosis and plantar fasciitis are key elements of our future musculoskeletal pipeline indications, and we are pleased to share information with the medical community on these important data,” stated James P. Tursi, MD, Executive Vice President, Global Research & Development at Endo.
Currently, CCH is not approved for treating plantar fibromatosis, but Endo is progressing with a pivotal Phase 3 program to further explore its potential efficacy and safety, aiming to offer new therapeutic options for those affected by this condition.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.